Biotechnology firm Pangaea Oncology has signed a new contract with German multinational corporation Merck, with a capital injection of more than €260,000. Specifically, Pangaea will conduct several in vitro experiments and analyse the prevalence of various genes of interest to Merck that are associated with drugs the company has in the clinical development phase. The aim is to find drug-use strategies for several subtypes of breast and lung cancer, under what is known as biomarker discovery.

Pangaea will give Merck access to its latest-generation laboratory and data-analysis capabilities to measure the prevalence in patients at its subsidiary, Dr Rosell Oncology Institute.

Source: ECSalud.com

Photo: Javier Rivela, CEO of Pangaea Oncology - © Pangaea Oncology